Boston, MA -- (SBWIRE) -- 12/24/2012 -- Global Market Direct's pharmaceuticals report, "Zeria Pharmaceutical Co Ltd - Product Pipeline Review - 2012" provides data on the Zeria Pharmaceutical Co Ltd's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Zeria Pharmaceutical Co Ltd's corporate website, SEC filings, investor presentations and featured press releases, both from Zeria Pharmaceutical Co Ltd and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Zeria Pharmaceutical Co Ltd - Brief Zeria Pharmaceutical Co Ltd overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Zeria Pharmaceutical Co Ltd human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Zeria Pharmaceutical Co Ltd with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Zeria Pharmaceutical Co Ltd's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Evaluate Zeria Pharmaceutical Co Ltd's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Zeria Pharmaceutical Co Ltd in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Zeria Pharmaceutical Co Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Zeria Pharmaceutical Co Ltd.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Zeria Pharmaceutical Co Ltd and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012
- Zeria Pharmaceutical Co Ltd - Product Pipeline Review - H2 2011
- Ono Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012
- Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012
- Kissei Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012
- BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2012
- Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012
- Simcere Pharmaceutical Group - Product Pipeline Review - 2012
- Dong-A Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012
- NeuroVive Pharmaceutical AB - Product Pipeline Review - 2012